CD274 and breast neoplasm: One study showed a decrease in PD-L1 expression by breast tumor cells during miR-200 overexpression, which may suggest that these data can be used in the treatment of breast cancer with PD-L1 inhibitors (durvalumab, avelumab, atezolizumab) [111].